Soros Fund Management’s Sarepta Therapeutics SRPT Stock Holding History

Soros Fund Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-230,893	Closed	-$28.1M	–	261
2024 Q4	$28.1M	Buy	230,893 +24,310	+12%	+$2.98M	0.42%	64
2024 Q3	$25.8M	Buy	+206,583	New	+$28.6M	0.37%	62
2024 Q2	–	Sell	-3,956	Closed	-$512K	–	223
2024 Q1	$512K	Buy	+3,956	New	+$485K	0.01%	191
2022 Q4	–	Sell	-101,500	Closed	-$11.2M	–	233
2022 Q3	$11.2M	Buy	+101,500	New	+$10.2M	0.19%	81
2014 Q4	–	Sell	-325,000	Closed	-$6.86M	–	265
2014 Q3	$6.86M	Sell	325,000 -355,000	-52%	-$8.01M	0.05%	182
2014 Q2	$20.3M	Buy	680,000 +655,000	+2,620%	+$20.7M	0.15%	114
2014 Q1	$601K	Sell	25,000 -208,000	-89%	-$5.3M	0.01%	259
2013 Q4	$4.75M	Sell	233,000 -432,274	-65%	-$12.8M	0.04%	184
2013 Q3	$31.4M	Buy	665,274 +239,585	+56%	+$9.23M	0.34%	70
2013 Q2	$16.2M	Buy	+425,689	New	+$15.2M	0.18%	97

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Soros Fund Management's SRPT Position: Q1 2025 in Review

Soros Fund Management sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 230,893 shares — an estimated $28.1M sold.

Soros Fund Management first reported a position in SRPT in Q2 2013 and held it in 10 quarters. The position peaked at $31.4M in Q3 2013. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

Soros Fund Management reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
Soros Fund Management sold 230,893 Sarepta Therapeutics shares in Q1 2025, an estimated $28.1M.
Soros Fund Management first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 10 quarters.
Soros Fund Management's Sarepta Therapeutics position peaked at $31.4M in Q3 2013.
430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on Soros Fund Management's 13F filing for Q1 2025, filed 15 May 2025.